Analysis of redox status and HDL subclasses in patients with lymphoma and the associations with FDG-PET/CT findings

被引:1
作者
Mirjanic-Azaric, Bosa [1 ,2 ]
Stankovic, Sinisa [3 ,4 ]
Nezic, Lana [5 ]
Radic Savic, Zana [1 ]
Malcic- Zanic, Dragana [6 ]
Skrbic, Ranko [5 ,7 ]
Kotur-Stevuljevic, Jelena [8 ]
Bogavac-Stanojevic, Natasa [8 ]
机构
[1] Univ Banja Luka, Fac Med, Dept Biochem, Banja Luka, Bosnia & Herceg
[2] Univ Clin Ctr Republ Srpska, Inst Lab Diag, Banja Luka 78000, Bosnia & Herceg
[3] Univ Clin Ctr Republ Srpska, Internal Med, Banja Luka, Bosnia & Herceg
[4] Univ Banja Luka, Fac Med, Banja Luka, Bosnia & Herceg
[5] Univ Banja Luka, Fac Med, Dept Pharmacol Toxicol & Clin Pharmacol, Banja Luka, Bosnia & Herceg
[6] Univ Banja Luka, Fac Med, Dept Pediat, Banja Luka, Bosnia & Herceg
[7] Acad Sci & Arts Republ Srpska, Banja Luka, Bosnia & Herceg
[8] Univ Belgrade, Fac Pharm, Dept Med Biochem, Belgrade, Serbia
关键词
redox status; HDL subclasses; SUVmax; Hodgkin lymphoma; non-Hodgkin lymphoma; OXIDATION PROTEIN PRODUCTS; HEALTH-ORGANIZATION CLASSIFICATION; TOTAL OXIDANT/ANTIOXIDANT STATUS; HIGH-DENSITY-LIPOPROTEIN; HODGKIN-LYMPHOMA; STRESS; LDL; CHOLESTEROL; PON1; CHEMOTHERAPY;
D O I
10.3389/fonc.2023.1221414
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Newer research points to alterations in the plasma redox status and the HDL subclass distributions in cancer. We aimed to assess the redox status and the HDL subclass distributions, lipids, and inflammatory markers in lymphoma patients in order to determine whether they were correlated with changes in FDG-PET/CT scans. At the beginning of this study, redox status, HDL subclasses, lipids, and inflammation biomarkers were determined in 58 patients with lymphoma (Hodgkin lymphoma, n=11 and non-Hodgkin lymphoma, n=47), and these same measurements were reassessed during their ensuing treatment (in 25 patients). Initially, the total oxidation status (TOS), the prooxidant-antioxidant balance (PAB), the OS index (OSI), the total protein sulfhydryl groups (SH-groups), and the advanced oxidation protein products (AOPP) were significantly higher in lymphoma patients as compared to healthy subjects, but the total antioxidant status (TAS) was significantly reduced. The PAB had a strong correlation with the CRP and interleukin-6 (rho=0.726, p<0.001; rho=0.386, p=0.003). The correlations between these parameters and the maximum standardized uptake values (SUVmax) were: PAB, rho=0.335 and p=0.010; SH-groups, rho=0.265 and p=0.044; CRP, rho=0.391 and p=0.002; HDL3b, rho=0.283 and p=0.031; HDL2b, rho= -0.294 and p=0.025; and HDL size, rho= -0.295 and p=0.024. The reductions in SUVmax between two follow-up points were associated with increases in the OSI, TOS, and SH-groups, as well as a reduction in the PAB and TAS. In conclusion, the redox parameters in patients with lymphoma were consistent with FDG-PET/CT findings. Targeting the redox status parameters and the HDL subclasses could be potential strategies in the molecular fight against lymphoma.
引用
收藏
页数:12
相关论文
共 50 条
[41]   18F-FDG PET/CT Findings in Primary Bilateral Adrenal Lymphoma [J].
Silov, Guler ;
Dogan, Serap ;
Kaya, Eser ;
Seker, Ozgul Turhal ;
Basbug, Esma Mehtap ;
Erdogan, Zeynep ;
Kandemir, Zuhal .
EUROPEAN JOURNAL OF GENERAL MEDICINE, 2014, 11 :38-40
[42]   Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview [J].
Ferrari, Cristina ;
Maggialetti, Nicola ;
Masi, Tamara ;
Nappi, Anna Giulia ;
Santo, Giulia ;
Niccoli Asabella, Artor ;
Rubini, Giuseppe .
JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (03) :NA
[43]   Dual-point FDG-PET/CT for treatment response assessment in Hodgkin lymphoma, when an FDG-avid lesion persists after treatment [J].
Borra, Anna ;
Morbelli, Silvia ;
Zwarthoed, Colette ;
Bianchi, Andrea ;
Bergesio, Fabrizio ;
Chauvie, Stephane ;
Zaucha, Jan M. ;
Taszner, Michel ;
Malkowski, Bogdan ;
Biggi, Alberto ;
Thyss, Antoine ;
Darcourt, Jacques ;
Gallamini, Andrea .
AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 9 (03) :176-184
[44]   Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVDxtwo cycles followed by FDG-PET/CT restaging and 20Gy of involved-site radiotherapy [J].
Kamran, Sophia C. ;
Jacene, Heather A. ;
Chen, Yu-Hui ;
Mauch, Peter M. ;
Ng, Andrea K. .
LEUKEMIA & LYMPHOMA, 2018, 59 (06) :1384-1390
[45]   Interim FDG-PET does not predict outcome in advanced-stage Hodgkin lymphoma patients treated with BEACOPP [J].
Adams, Hugo J. A. ;
Kwee, Thomas C. .
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (04) :758-760
[46]   Consistency of FDG-PET Accuracy and Cost-Effectiveness in Initial Staging of Patients With Hodgkin Lymphoma Across Jurisdictions [J].
Cerci, Juliano J. ;
Trindade, Evelinda ;
Buccheri, Valeria ;
Fanti, Stefano ;
Coutinho, Artur M. N. ;
Zanoni, Lucia ;
Linardi, Camila C. G. ;
Celli, Monica ;
Delbeke, Dominique ;
Pracchia, Luis F. ;
Pitela, Felipe A. ;
Soares, Jose, Jr. ;
Zinzani, Pier Luigi ;
Meneghetti, Jose C. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (04) :314-320
[47]   FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma [J].
Rajamaki, Aino ;
Kuitunen, Hanne ;
Sorigue, Marc ;
Kokkonen, Salla-Maarit ;
Kuittinen, Outi ;
Sunela, Kaisa .
CANCER MEDICINE, 2023, 12 (01) :407-411
[48]   Diagnosis of bone marrow involvement in angioimmunoblastic T-cell lymphoma should be based on both [18F]FDG-PET/CT and bone marrow biopsy findings [J].
Liang, Xinyu ;
Yang, Chunli ;
Su, Minggang ;
Zou, Liqun .
CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (05) :803-811
[49]   18F-FDG PET/CT in the clinical management of patients with lymphoma [J].
Tamayo, P. ;
Martin, A. ;
Diaz, L. ;
Cabrero, M. ;
Garcia, R. ;
Garcia-Talavera, P. ;
Caballero, D. .
REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2017, 36 (05) :312-321
[50]   Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy [J].
Hugo J. A. Adams ;
Rutger A. J. Nievelstein ;
Thomas C. Kwee .
Annals of Hematology, 2016, 95 :1-9